


## Performance (%) <sup>1</sup>

|                               | 1 month | 3 months | 1 year | 3 years p.a. | 4 years p.a. | 5 years p.a. | Since inception<br>p.a. (31 May 1998) |
|-------------------------------|---------|----------|--------|--------------|--------------|--------------|---------------------------------------|
| <b>Fund <sup>2</sup></b>      | 2.0     | 2.7      | 12.2   | 10.2         | 10.8         | 9.5          | 8.2                                   |
| <b>Benchmark <sup>3</sup></b> | 0.7     | 4.0      | 6.1    | 10.6         | 11.6         | 7.8          | 8.6                                   |

## Cumulative value of AUD \$20,000 invested



## Portfolio characteristics <sup>4</sup>

|                                             | Fund | Market overall <sup>5</sup> |
|---------------------------------------------|------|-----------------------------|
| Price: Earnings ratio                       | 14.7 | 17.3                        |
| Price: Cash flow ratio                      | 9.0  | 11.9                        |
| Price: Net tangible assets ratio            | 2.5  | 1.4                         |
| Grossed up dividend yield %                 | 5.7  | 4.7                         |
| Balance sheet strength <sup>6</sup>         | 0.27 | 0.35                        |
| Growth in earnings per share % <sup>7</sup> | 6.3  | 6.4                         |

## Top 5 holdings (%)


## Weighting

|                           |      |
|---------------------------|------|
| BHP Group                 | 13.5 |
| ANZ Group                 | 7.0  |
| CSL                       | 5.7  |
| Insurance Australia Group | 5.0  |
| Woodside Energy Group     | 4.3  |

## Risk measures

|                                        | Fund | Benchmark |
|----------------------------------------|------|-----------|
| Monthly volatility % p.a. <sup>8</sup> | 12.5 | 13.1      |
| Tracking error (ex-ante) <sup>9</sup>  | 6.3  |           |
| Beta vs Benchmark <sup>9</sup>         | 0.7  |           |

## Fund sector weight (%)



## Annual distributions

|              | Cents per unit | Distribution return % |
|--------------|----------------|-----------------------|
| 30 June 2026 | 11.8244        | 13.2                  |
| 30 June 2025 | 8.8545         | 9.5                   |
| 30 June 2024 | 8.4733         | 9.5                   |
| 30 June 2023 | 5.6489         | 6.8                   |
| 30 June 2022 | 10.2082        | 10.8                  |

### Notes:

1 Past performance is not a reliable indicator of future performance. Source: Maple-Brown Abbott Ltd, S&P as at 30 June 2026.

2 The Fund's performance relates to Class W investors only. If you are a Class R investor, you can obtain up to date returns at [maple-brownabbott.com](http://maple-brownabbott.com). Total return is based on the movement in withdrawal price per unit plus distributions and is before tax and after all fees and charges. Imputation credits and foreign income tax offsets are not included in performance figures.

3 The benchmark is S&P/ASX 200 Total Return Index.

4 The portfolio characteristics are based on the underlying securities held within the Fund/market overall. The figures shown for the Fund are our own estimates for the next 12 months having regard to available information on the underlying companies as at 30 June 2026 and are subject to change without notice. The market overall is an estimate for the next 12 months based on estimates from FactSet and Maple-Brown Abbott. These figures are based on certain assumptions (including forecasting a company's earnings, profit, cash flows, balance sheet, estimating payout ratio and franking levels) which may be inaccurate or impacted by unknown risks. Actual outcomes may vary in a materially positive or negative manner.

5 The market overall data represents our quantitative data which includes 97.8% of the index weight of the stocks in the benchmark, plus non-benchmark stocks.

6 Balance sheet strength is calculated as cash flow/total liabilities. Refer footnote 4 for further detail.

7 This number is a 4 year estimate. The figures shown for the Fund are our own estimates having regard to available information on the underlying companies as at 30 June 2026 and are subject to change without notice. The market overall is an estimate based on estimates from FactSet and Maple-Brown Abbott.

8 Volatility is at since inception 31 May 1998. The volatility is calculated for both the Fund and benchmark. Volatility calculation is annualised and is the standard deviation of monthly returns.

9 Source: UBS as at 30 June 2026.

## Overview

The Maple-Brown Abbott Australian Share Fund – Class W (the “Fund”) is invested in companies listed (or expected to be listed) on an Australian securities exchange and is actively managed. Our value-based investment philosophy underlies our approach to stock selection, driven by our bottom-up research process designed to maximise the opportunities to deliver income and long-term capital growth to our clients. We use several valuation screens to rank our investment universe and generate stock ideas. Our experienced team then undertakes detailed quantitative and qualitative analysis to identify companies that are trading at a discount to our assessment of their underlying value. The Fund provides exposure to a diversified portfolio of our highest conviction opportunities which we expect to deliver strong risk-adjusted returns over the long-term. We aim to invest across a broad universe of Australian companies and will typically hold 25–40 stocks.

## Fund snapshot

### Objective

The Fund aims to outperform the S&P/ASX 200 Total Return Index (Benchmark), after fees, over a four-year period.

### Asset allocation ranges

|                     |         |
|---------------------|---------|
| Australian equities | 85-100% |
| Cash                | 0-15%   |

## Fund facts

|                                         |             |
|-----------------------------------------|-------------|
| Fund size                               | \$300m      |
| Inception date                          | 31 May 1998 |
| APIR code                               | ADV0046AU   |
| Distribution frequency                  | Quarterly   |
| Management fees and costs <sup>10</sup> | 0.80% p.a.  |
| Minimum investment <sup>10</sup>        | \$20,000    |
| Minimum withdrawal <sup>10</sup>        | \$10,000    |
| Buy/sell spread <sup>10</sup>           | 0.19%/0.19% |
| Application price (AUD)                 | \$0.9115    |
| Redemption price (AUD)                  | \$0.9081    |

Notes:

<sup>10</sup> Additional fees and costs may also apply in relation to an investment in the Fund. For a full description of the fees and costs refer to the Fund Product Disclosure Statement (“PDS”) and Additional Information Booklet (“AIB”) for the Fund.

## Investment philosophy

Value, active, bottom up

## Portfolio Manager

Dougal Maple-Brown

## Fund ratings



Signatory of:



## Further information

Contact our Client Service team by:

T +61 2 8059 7671

E [invest@maple-brownabbott.com](mailto:invest@maple-brownabbott.com)

## Australian Head Office

Maple-Brown Abbott Limited

Level 25, Australia Square Tower

264 George Street, Sydney NSW 2000

## UK Office

Antipodes Partners Limited

Suite 823

125 Old Broad Street

London EC2N 1AR UK

## Disclaimer

This information has been prepared by Antipodes Partners Limited (“Antipodes”) (ABN 29 602 042 035, AFSL 481 580) as the Investment manager of the Maple-Brown Abbott Australian Share Fund - Class W (ARSN 087 294 504) (“Fund”). Maple-Brown Abbott Limited (“MBAL”) (ABN 73 001 208 564, AFSL 237296), is the Responsible Entity for the Maple-Brown Abbott Australian Share Fund - Class W. MBAL is a subsidiary of Antipodes Partners Holdings PTY LTD (ABN 91 602 828 526).

This report contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent financial advice. This document does not constitute an offer or solicitation by anyone in any jurisdiction. Past performance is not a reliable indicator of future performance. Neither MBAL, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment.

Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. Individual stocks referred to may or may not be currently held by the Fund. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications not described in this document. To the extent permitted by law, neither MBAL, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current PDS and Target Market Determination (TMD) or any other relevant disclosure document. For the Fund, the PDS, AIB and TMD are available at <https://maple-brownabbott.com/document-library/> or by calling 1300 097 995.

**Lonsec:** The Lonsec Rating (assigned as follows: Maple-Brown Abbott Australian Share Fund - Class W – November 2025) presented in this document are published by Lonsec Research presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to “General Advice” (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec’s Ratings methodology, please refer to our website at <https://www.lonsec.com.au/>.

**Zenith:** The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (assigned Maple-Brown Abbott Australian Share Fund - Class W – June 2026) referred to on this website is limited to “General Advice” (s766B Corporations Act 2001) for Class W clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at [Fund Research Regulatory Guidelines](#).